Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.45 |
| ▸ | CCR1 | P32246 | 3/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125906 | 0.91 | ELANE (0.49) | ELANECCR1NOTUMSMN1; SMN2NPY5R | |
| SCHEMBL4131125 | 0.90 | ELANE (0.53) | ELANECYP2C9 | |
| SCHEMBL8218336 | 0.89 | ELANE (0.43) | ELANECCR1NOTUMSMN1; SMN2NPY5R | |
| SCHEMBL8220444 | 0.88 | NOTUM (0.53) | ELANECCR1NOTUMSMN1; SMN2NPY5R | |
| SCHEMBL8218340 | 0.87 | NOTUM (0.44) | ELANECCR1NOTUMSMN1; SMN2NPY5R | |
| SCHEMBL4131073 | 0.86 | ELANE (0.66) | ELANE | |
| SCHEMBL8217868 | 0.86 | ELANE (0.41) | ELANECCR1NOTUMSMN1; SMN2NPY5R | |
| SCHEMBL8218349 | 0.85 | ELANE (0.40) | ELANECCR1NOTUMSMN1; SMN2NPY5R | |
| SCHEMBL4141673 | 0.83 | ELANE (0.48) | ELANECCR1NOTUMSMN1; SMN2NPY5R | |
| SCHEMBL4135846 | 0.83 | ELANE (0.48) | ELANECCR1NOTUMSMN1; SMN2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | claimed |
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | ELANE 2/4885CCR1 208/4885NOTUM 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.